Counseling Patients About Ovarian Cancer Prevention Strategies for BRCA Carriers and Other High-Risk Groups

References

1. Bogani G, Tagliabue E, Signorelli M, Chiappa V, Carcangiu ML, Paolini B, et al. Assessing the risk of occult cancer and 30-day morbidity in women undergoing risk-reducing surgery: a prospective experience. J Minim Invasive Gynecol 2017;24:837-42. doi: 10.1016/j.jmig.2017.04.017
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33. doi: 10.1200/JCO.2006.09.1066
3. Eoh KJ, Park EY, Chang YJ, Ha HI, Hong J, Huang D, et al. The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: a systematic review and meta-analysis. Gynecol Oncol 2021;163:142-7. doi: 10.1016/j.ygyno.2021.07.028
4. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 2009;112:594-600. doi: 10.1016/j.ygyno.2008.11.039
5. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 3.2024. NCCN Clinical Practice Guidelines in Oncology [after login]. NCCN; 2024. Accessed July 31, 2024. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
6. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 2013;122:139-47. doi: 10.1097/AOG.0b013e318291c235
7. Hereditary breast and ovarian cancer syndrome. Practice Bulletin No 182. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e110-26. doi: 10.1097/AOG.0000000000002296
8. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15. doi: 10.1056/NEJMoa020119
9. Komata D, Yahata T, Kodama S, Koyama Y, Takeda N, Tajima K, et al. The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects. J Obstet Gynaecol Res 2009;35:912-7. doi: 10.1111/j.1447-0756.2009.01090.x
10. Kotsopoulos J, Gronwald J, McCuaig JM, Karlan BY, Eisen A, Tung N, et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 2020;159:820-6. doi: 10.1016/j.ygyno.2020.09.037
11. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005;23:6890-8. doi: 10.1200/JCO.2005.02.626
12. Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen L. Disparities in genetics assessment for women with ovarian cancer: can we do better? Gynecol Oncol 2018;149:84-8. doi: 10.1016/j.ygyno.2017.10.034
13. Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 2014;14:150-5. doi: 10.1186/s12905-014-0150-5
14. Meiser B, Price MA, Butow PN, Karatas J, Wilson J, Heiniger L, et al. Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer. Fam Cancer 2013;12:101-9. doi: 10.1007/s10689-012-9585-8
15. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7. doi: 10.1093/jnci/djn442
16. Royal College of Obstetricians and Gynaecologists. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Scientific Impact Paper No. 44. RCOG; 2014. Accessed July 24, 2024. https://www.rcog.org.uk/media/s0nlcrlx/sip44hgscs.pdf
17. Simon MS, Petrucelli N. Hereditary breast and ovarian cancer syndrome: the impact of race on uptake of genetic counseling and testing. Methods Mol Biol 2009;471:487-500. doi: 10.1007/978-1-59745-416-2_25
18. Soegaard M, Frederiksen K, Jensen A, Høgdall E, Høgdall C, Blaakaer J, et al. Risk of ovarian cancer in women with first-degree relatives with cancer. Acta Obstet Gynecol Scand 2009;88:449-56. doi: 10.1080/00016340902807207
19. Walker JL, Powell CB, Chen L, Carter J, Bae Jump VL, Parker LP, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 2015;121:2108-20. doi: 10.1002/cncr.29321
20. Wu AH, Pearce CL, Lee AW, Tseng C, Jotwani A, Patel P, et al. Timing of births and oral contraceptive use influences ovarian cancer risk. Int J Cancer 2017;141:2392-9. doi: 10.1002/ijc.30910